Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Phase 3
Completed
NCT03260894
| Condition | Renal Cell Carcinoma |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Incyte Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 129 participants |
|---|
| Interventions | Pembrolizumab, Epacadostat, Sunitinib, Pazopanib |
|---|
| Start date | Dec 7, 2017 |
|---|
| Completion date | Aug 22, 2018 |
|---|
| Results posted | Sep 10, 2019 |
|---|
Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)
up to approximately 8 months · percentage of participants
| Pembrolizumab + Epacadostat | 1.6 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 0.0 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 29.7 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
| Pembrolizumab + Epacadostat | 31.3 percentage of participants |
|---|
| SoC (Sunitinib or Pazopanib) | 29.2 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.